Oral Mucositis in Patients Undergoing Immunotherapy: A Case Study

Abstract

Oral mucositis is a common complication of cancer therapy, characterised by inflammation and ulceration of the oral mucosa. Immunotherapy, while effective against cancer, can also lead to oral mucosal toxicities, impacting patients' quality of life and treatment outcomes. This case study presents a 65-year-old male with metastatic squamous cell carcinoma of the lung undergoing immunotherapy with Pembrolizumab who developed severe oral mucositis. Clinical examination revealed whitish pseudo membranes, erosions, and pus discharge, resulting in pain, dysphagia, and halitosis. Symptomatic treatment was provided, focusing on pain relief and oral hygiene maintenance. Management strategies included oral rinses, topical agents, hydration, and dietary modifications. The case highlights the importance of early detection and intervention in managing oral mucositis in patients undergoing immunotherapy, aiming to alleviate symptoms, maintain treatment adherence, and improve patient outcomes.